Zero Cost EMI for CAR-T Therapy to Boost Healthcare Accessibility

Immuneel and Arogya Finance have introduced India's first zero cost EMI programme for Qartemi CAR-T therapy, a significant move towards making cancer treatment more accessible. This initiative aims to reduce the financial burden on patients who require this advanced therapy, which is crucial for certain blood cancers. Qartemi CAR-T therapy is a revolutionary treatment designed for patients with acute lymphoblastic leukaemia and large B-cell lymphoma. It works by modifying a patient’s T cells to better identify and combat cancer cells. While the therapy has shown encouraging results, the high cost can be a barrier for many families, with expenses reaching up to ₹30 lakh. To tackle this issue, the zero cost EMI programme allows patients to pay for the treatment over time without any interest charges. This flexibility is expected to significantly relieve the financial pressure on families, allowing them to focus on recovery rather than financial concerns. The partnership between Immuneel, a biotechnology leader in CAR-T therapy, and Arogya Finance, which specializes in making healthcare affordable, is a strategic move to provide patients with more manageable payment options. This collaboration is essential in ensuring that financial limitations do not prevent access to life-saving treatments. The benefits of this initiative are clear. It increases accessibility to advanced cancer treatments for a wider patient base, eliminates interest charges, and enhances financial planning for patients. This new approach is a crucial step in improving healthcare accessibility in India. The launch of the zero cost EMI programme for Qartemi CAR-T therapy by Immuneel and Arogya Finance represents a significant advancement in making advanced cancer treatments financially viable for patients in India. This initiative underscores the importance of innovative financial solutions in enhancing healthcare accessibility. Based on reports from Google News — Finance India.